Organon & Co | OGN - Operating Expenses


Organon & Co reported $903M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Celltrion KRW 140.68B 584.31B Dec/2025
Cspc Pharmaceutical CNY 5.91B 512.77M Dec/2025
Deva Holding AS TRY 1.35B 178.26M Sep/2023
Dianthus Therapeutics USD 69.82M 29.14M Dec/2025
Divis Laboratories Ltd INR 20.17B 1.85B Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Kangmei Pharma CNY 1.09B 304.02M Mar/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Laboratorios Farma EUR 313.62M 17.98M Dec/2023
Malin Corporation EUR 1.1M 400K Dec/2024
Medical Developments International AUD 21.61M 11.59M Dec/2025
Merck USD 18.17B 8.01B Mar/2026
Neuren Pharmaceuticals AUD 25.23M 16.54M Dec/2025
Novartis USD 9.8B 23M Dec/2025
Organigram Holdings CAD 83.66M 24.44M Dec/2025
Organon & Co USD 903M 387M Mar/2026
Ovoca Bio EUR 1.16M 4.48M Jun/2025
Pharma Mar EUR 42.28M 4.59M Mar/2026
Qiagen NV USD 418.54M 23.25M Dec/2025
Sartorius EUR 738.4M 22.4M Mar/2026
Sino Biopharmaceutical CNY 12.39B 1.26B Jun/2025
Tilray USD 237.52M 17.34M Sep/2025
Zealand Pharma A/S 775.97M 265.08M Dec/2025